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The ability of methylly~conitine (MLA) to inhibit the binding of ezsI~-bungarotoxin to rat brain membranes, frog and human muscle extracts 
and the human muscle cell line TE671 has been measured. MLA showed a markedly higher affinity for the rat brain site (Ki 1.4 x IO* M) than 
for the muscle receptors (4 1O-s-1O-6 M). Structure modelling techniques were used to fit the structure of MLA to a nicotinic pharmacophore 
model. MLA is the first low molecular weight ligand to be shown to discriminate between muscle nicotinic receptors and their a-bungarotoxin- 
binding counterpart in the brain, and as such may be a useful structural probe for pursuing the structural and functional properties of the neuronal 
protein. 
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1. INTRODUCTION 
The alkaloid N-methyllycaconitine (MLA; Fig. 1) is 
the principal toxic component of the seeds of 
Delphinium brownii. Historically, the seeds from this 
plant have been recognized for their insecticidal proper- 
ty, which is believed to arise from the potent an- 
tagonism of insect nicotinic a~etylcholine receptors 
(nAChR) by MLA [I]. MLA is a potent competitor of 
[‘251]cY-bungarotoxin b ding to nAChR in flyheads [ 11, 
locust ganglia [2] and cockroach nerve cord [3], with Ki 
values in the nanomolar range. Complete blockade of 
nicotinic responses from a cockroach motorneurone 
was observed at 10e6 M MLA; the EDSO for this an- 
tagonism was about lo- 7 M [3], which is comparable to 
the sensitivity to MLA of acetylcholine responses in the 
nematode Ascaris [4]. This potency contrasts with the 
weaker antagonism by MLA of mammalian nAChR at 
the rat neuromus~ul~ junction (EDSO 2 x 10e6 M) f5]. 
In a previous study [2] we compared the potencies of 
MLA in competition binding assays for locust and rat 
neuronal nAChR, and reported that the [1251]~- 
bungarotoxin binding site in mammalian brain was 3 
orders of magnitude more sensitive to MLA than was 
the putative nAChR labelled by E3H]nicotine in the 
same tissue. Apart from the snake a-toxins, this is the 
only example of a cholinergic compound that is more 
potent at the a-bungarotoxin site than the t3H]nicotine 
site. Thus the insect and rat brain [“‘I]~-bungarotoxin 
binding sites share a common sensitivity to MLA. In 
view of the current uncertainty about the physiological 
status of [‘251]cu-bungarotoxin bi ding sites in the mam- 
malian CNS (see [6,7]), a pharmacological probe show- 
ing selectivity for this site would be very useful. 
Although the rw-bungarotoxin binding component in 
vertebrate brain shows homology with nAChR at the 
protein [S] and gene [7] level, there is little direct 
evidence that this protein has any role in synaptic 
transmission in the brain, despite its clear nicotinic 
pharmacology in binding experiments. Exceptions in- 
clude the chick optic tectum [S] and cerebellar in- 
terneurones [9], where ~-bungarotoxin has been shown 
to antagonize nicotinic responses. In insects, however, 
the neuronal or-bungarotoxin binding protein is well 
documented as a functional nAChR [lo], The potency 
of MLA for neuronal a-bungarotoxin sites, both mam- 
malian and invertebrate, has prompted us to further 
assess its specificity by comparing its potencies in com- 
petition binding assays for nAChR in vertebrate muscle 
preparations and to consider the molecular basis for its 
pharmacological specificity. 
2. MATERIALS AND METHODS 
2.1. MOrerials 
Correspondence address: S. Wonnacott, Department of 
Biochemistry, University of Bath, Bath BA2 7AY, UK 
*Present address: Department of Anesthesiology, Harvard Medical 
School, Shriners Burns Institute, Boston, MA, USA 
Na ‘*‘I was purchased from Amersham International (Aylesbury, 
UK). cY-Bungarotoxin was purchased from Sigma (Poole, UK) and 
iodinated to a specific activity of 700 Ci/mmol as pieviously described 
[l 11. Tissue culture reagents were obtained from Flow Laboratories, 
Irvine, Ayrshire, UK or Gibco Ltd., Uxbridge Middlesex, UK. All 
sterile plastic ware was supplied by Nunc Gibco Ltd. TE671 cells were 
kindly provided by Professor J. Newsom-Davis (Institute for 
Molecular Neuroscience, John Radcliffe Hospital, Oxford, UK) and 
were cultured in monolayers in 80 cm3 flasks, essentially as described 
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Fig. 1. Structures of MLA, acetylcholine and cystisine. Hydrogen 
atoms are not shown. Unlabelled atoms are carbon. Arrows indicate 
the key atoms implicated in the pharmacophore model of nicotinic 
cholinergic ligand binding [20]. The dashed box encloses the parent 
structure, lycotonine. The N-phenyl-succinimide side chain of MLA 
is on the left. 
by Syapin et al. (121 with modifications [13]. MLA (citrate salt) was 
synthesized by Professor M.H. Benn (Department of Chemistry, 
University of Calgary, Alberta, Canada). 
2.2. Competition binding assays 
Rat brain P2 membranes, frog muscle extract and human muscle 
extract were prepared and assayed for [‘*‘I]cY-bungarotoxin binding 
as previously described [2,14,15]. TE671 cells were harvested and 
replated in fresh growth medium in 24-well plates at a cell density of 
5 x lo5 cells/ml, essentially as previously described [12,13]. 
Triplicate wells were incubated with serial dilutions of MLA and 
[“‘I]~-bungarotoxin (final concentration 2.0 nM) for 90 min at 37°C. 
Non-speficic binding was determined in the presence of 1 .O mM D- 
tubocurarine. After incubation, cells were washed and extracted in 
0.1 M NaOH for determination of radioactivity. 
2.3. Structure modelling 
The programs Discover and Insight from Biosym Inc. were used to 
construct and view structures on an Evans and Sutherland PS 300 pic- 
ture system. Energy calculations were performed using the valence 
force-field with the potential parameters of Dauber-Osguthorpe etal. 
[16]. MLA was constructed using the X-ray structure of aconitine 
[17], and the stereochemistry of MLA as reported by Jennings et al. 
[l]. The S- and 6-membered rings of the N-phenylsuccinimide moiety 
of MLA were set orthogonal, based on the X-ray structure of N-p- 
bromophenyl-succinimide. The rigid nicotinic agonist, cystisine, was 
used as a template in the establishment of a nicotinic cholinergic phar- 
macophore. Site-points used to overlay MLA and acetylcholine onto 
cystisine were: the nitrogen atom of the ammonium group; the carbon 
atom of the carbonyl group; and the oxygen atom of the carbonyl 
group. Acetylcholine and MLA were template-fitted onto cystisine us- 
ing a forcing constant of 25 kcal/mol [18]. 
3. RESULTS AND DISCUSSION 
Competition binding assays with MLA were carried 
out on rat brain membranes, frog and human muscle 
extracts and the human rhabdomyosarcoma cell line 
TE671 (Fig. 2). Inhibition constants (the concentration 
of MLA that inhibits [“‘I]cr-bungarotoxin binding by 
50%) are given in Table I. In agreement with our 
previous findings [2], MLA was a very potent inhibitor 
of [1251]a-bungarotoxin binding to rat brain mem- 
branes. However, it was more than 3 orders of 
magnitude weaker in competing for the muscle nAChR 
in each of the preparations tested. Notably, human 
muscle extract, prepared from amputated calf muscle 
[ 151, and the TE67 1 cell line displayed similar Ki values 
(approximately 10e5 M) for MLA. The sensitivity of 
muscle nAChR to MLA is very comparable to that 
previously derived for Torpedo NaChR and brain 
t3H]nicotine binding sites [2] (see Table I). At 10m4 M, 
MLA had no muscarinic potency, indicated by its 
failure to inhibit [3H]quinuclidinyl benzilate binding to 
rat brain membranes (data not shown). 
The unique discrimination by MLA in favour of 
neuronal versus muscle a-bungarotoxin binding sites 
raises the issue of the structural features that underlie 
the recognition of this compound; the definition of 
such features would aid our understanding of the 
molecular nature of the nicotinic receptor recognition 
site. The parent structure, lycoctonine [l] (see Fig. l), is 
without nicotinic potency; indeed it is closely related to 
aconitine which interacts with sodium channels at the 
site characterized by batrachotoxin [ 191. The introduc- 
tion of an ester linkage in the formation of MLA pro- 
vides a carbonyl oxygen (Fig. 1, arrow l), that is likely 
to be a key moiety in conferring cholinergic nicotinic ac- 
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Fig. 2. Competition curves for MLA in various nAChR preparations. 
Rat brain membranes (O-O), detergent extracts of frog (o---+) 
and human (&---A) muscle, and culture dishes of TE671 cells 
(ti) were incubated with serial dilutions of MLA and 2 nM 
[‘251]cY-bungarotoxin. Non-specific binding was determined in the 
presence of unlabelled a-bungarotoxin. Values are the means of at 
least 3 separate assays with SEM indicated by the vertical bars. 
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Table I 
Inhibition of radioligand binding to nAChR preparations by MLA 
Preparation Ligand Ki (M) for MLA 
Frog muscle extract [rz51]c+Bgt 1.0 f 0.2 x 10-5 
Human muscle extract [‘Z5]cu-Bgt 7.8 f 2.0 x 10-6 
TE67 1 cells [1251]a-Bgt 6.3 f 1.4 x 1O-5 
Rat brain P2 membranes [L251](U-Bgt 1.4 f 0.2 x 10-9 
Rat brain P2 membranes [‘HInicotine 3.7 r3.7 x lo-6* 
Torpedo purified nAChR [1251]~-Bgt 1.1 f 0.6 x 10-6* 
Locust ganglion [‘251]ru-Bgt 1.8 x 10-8* 
Competition assays weer performed using 2 nM [rz51]a-Bgt. 1C50 
values were derived from linear transformations of dose-response 
curves; Ki values were derived from ICso values (261, assuming & 
values for [1251]cy-Bgt of 1.8 nM (frog muscle [14]), 0.5 nM (human 
muscle [15]), 2.0 nM (TE671 cells; Ward, unpublished observations), 
1.5 nM (brain [2]). Values are the means f SE for at least 3 
independent determinations. *Data from (21 for comparison. 
tivity on this structure. This electronegative centre is a 
feature of nicotinic ligands, and is considered to be in- 
volved in hydrogen bonding with key residues at the 
recognition site [20]. 
In addition, this pharmacophore model [20] of 
nicotinic ligands includes an electrostatic interaction 
between the quaternary nitrogen of acetylcholine and 
the receptor binding site. Using the rigid agonist 
cytisine as a definitive template, acetylcholine and 
MLA were superimposed to generate the conformations 
illustrated in Fig. 1 (see Materials and Methods). Thus 
we can identify the nitrogen atom in MLA for similar 
electrostatic interaction (Fig. 1; arrow 2). 
How can we account for the marked preference 
shown by MLA for neuronal a-bungarotoxin binding 
sites compared with other members of the nicotinic 
receptor family of proteins? The precise spatial rela- 
tionship between the key residues contributing to the 
receptor binding site [21,22] may vary among receptor 
subtypes and hence could influence the affinity of bin- 
ding of MLA. Sequence analysis of the two (Y- 
bungarotoxin binding proteins recently cloned from 
chick brain [7] shows them to have lower homology 
with other avian nicotinic receptor subunits (less than 
50% in every case [7]) than there is between neuronal 
and muscle nicotinic receptor subunits. That is to say, 
within the same species the enigmatic brain a- 
bungarotoxin binding protein is less similar to the mus- 
cle nicotinic receptor, which also binds a-bungarotoxin 
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Fig. 3. Classification of nicotinic receptors based on their high 
affinity binding of MLA, or-bungarotoxin and nicotine. 
(see Fig. 3) than are the neuronal nicotinic receptors 
that do not recognize this snake toxin. However, com- 
parison of the chick brain cr-bungarotoxin binding pro- 
tein sequences with that of an a-subunit cloned from 
locust ganglion [23] reveals considerably greater 
homology, especially in the rather variable extracellular 
domain. In particular, there is high homology in the se- 
quences flanking the vicinal cysteines (Cys 192 and 193 
Torpedo numbering) that are implicated in the nicotinic 
ligand binding site [24]. Whereas the oxygen-rich bulk 
of the lycoctonine portion of MLA (Fig. 1) might be ex- 
pected to face into the solvent around the binding site, 
the N-phenylsuccinimide side chain is topologically 
equivalent o the reactive group in ligands that label Cys 
192 and 193 [24]. Thus this side chain may be accom- 
modated in this region of the protein, the amino acid se- 
quence of which will influence the relative binding af- 
finities for MLA. The homology between chick brain CY- 
bungarotoxin binding proteins and locust nAChR is 
likely to underlie the high affinity binding of MLA 
shared by these proteins (Table I). 
The possible relationships in receptor structure that 
are reflected in the pharmacological similarities are 
outlined in Fig. 3. It should be noted however that the 
pharmacological discrimination is not absolute; both 
muscle nAChR and the high affinity nicotine binding 
site in brain show a low affinity for MLA (Table I), and 
all the nicotinic proteins, by definition, recognize 
nicotine to some extent. Indeed we have recently shown 
that micromolar concentrations of MLA antagonize 
functional responses of neuronal nAChR that are insen- 
sitive to a-bungarotoxin [25]. 
We suggest hat MLA is a potentially useful probe in 
the dissection of subtypes of nAChRs. Synthesis of 
analogues of MLA may well provide more definitive 
answers to some of the proposals made here and may 
help in defining more precisely the site(s) of ligand 
recognition in this important family or neuronal recep- 
tor proteins. 
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